Aerovate Therapeutics Terminates Merger with Hansoh Pharma
Ticker: JBIO · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1798749
Sentiment: bearish
Topics: merger-termination, regulatory-approval, ftc
TL;DR
FTC blocked the Hansoh Pharma deal, Aerovate gets $0, deal dead.
AI Summary
On June 17, 2024, Aerovate Therapeutics, Inc. filed an 8-K report detailing the termination of its merger agreement with Jiangsu Hansoh Pharmaceutical Group Co., Ltd. The termination was due to the failure to obtain regulatory approval from the U.S. Federal Trade Commission (FTC) by the agreed-upon deadline. Consequently, the merger, which was expected to provide Aerovate with approximately $200 million in cash, will not proceed.
Why It Matters
This termination means Aerovate Therapeutics will not receive the anticipated $200 million cash infusion, potentially impacting its financial runway and future development plans.
Risk Assessment
Risk Level: high — The termination of a significant merger agreement due to regulatory hurdles poses a substantial risk to the company's financial stability and strategic direction.
Key Numbers
- $200 million — Expected Merger Proceeds (This was the anticipated cash infusion Aerovate Therapeutics would receive upon completion of the merger with Jiangsu Hansoh Pharmaceutical Group.)
Key Players & Entities
- Aerovate Therapeutics, Inc. (company) — Registrant
- Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (company) — Acquiring company in terminated merger
- U.S. Federal Trade Commission (FTC) (company) — Regulatory body that blocked the merger
- $200 million (dollar_amount) — Expected cash infusion from the terminated merger
- June 17, 2024 (date) — Date of the 8-K filing and earliest event reported
FAQ
What was the primary reason for terminating the merger agreement between Aerovate Therapeutics and Jiangsu Hansoh Pharmaceutical Group?
The merger agreement was terminated because Aerovate Therapeutics failed to obtain the necessary regulatory approval from the U.S. Federal Trade Commission (FTC) by the agreed-upon deadline.
What was the expected financial benefit for Aerovate Therapeutics from this merger?
Aerovate Therapeutics was expected to receive approximately $200 million in cash upon the successful completion of the merger.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 17, 2024.
Which regulatory body was involved in blocking the merger?
The U.S. Federal Trade Commission (FTC) was the regulatory body that did not approve the merger, leading to its termination.
What is Aerovate Therapeutics, Inc.'s principal executive office address?
Aerovate Therapeutics, Inc.'s principal executive offices are located at 930 Winter Street, Suite M-500, Waltham, Massachusetts 02451.
Filing Stats: 804 words · 3 min read · ~3 pages · Grade level 9.2 · Accepted 2024-06-17 08:35:53
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share AVTE The Nasdaq
- $100 million — ne 15, 2024, Aerovate has approximately $100 million of cash, cash equivalents and short-ter
Filing Documents
- tm2417394d1_8k.htm (8-K) — 35KB
- tm2417394d1_ex99-1.htm (EX-99.1) — 20KB
- tm2417394d1_ex99-1img001.jpg (GRAPHIC) — 15KB
- 0001104659-24-072058.txt ( ) — 253KB
- avte-20240617.xsd (EX-101.SCH) — 3KB
- avte-20240617_lab.xml (EX-101.LAB) — 33KB
- avte-20240617_pre.xml (EX-101.PRE) — 22KB
- tm2417394d1_8k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On June 17, 2024, Aerovate Therapeutics, Inc. ("Aerovate" or the "Company") issued a press release titled "Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension." A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information under Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Other Events
Item 8.01 Other Events On June 17, 2024, the Company announced topline results from the Phase 2b portion of the Phase 2b/Phase 3 Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial ("IMPAHCT"). Results showed that, while AV-101 was well tolerated across all dose groups, the study did not meet its primary endpoint for improvement in pulmonary arterial hypertension ("PVR") compared to placebo for any of the studied doses or show meaningful improvements in the secondary endpoint of change in six minute walk distance ("6MWD"). P rimary Endpoint – ITT analysis of PVR (dynes*sec/cm^5) Dose Least-squares mean difference as compared with placebo (95% CI) P value 10mg BID (N=50) 42.8 (-80.57 to 166.09) 0.4968 35mg BID (N=49) -5.5 (-129.16 to 118.18) 0.9306 70mg BID (N=51) -57.0 (-181.14 to 67.20) 0.3685 Secondary Endpoint – ITT analysis of 6MWD (meters) Dose Least-squares mean difference as compared with placebo (95% CI) 10mg BID (N=50) -11.7 (-34.75 to 11.26) 35mg BID (N=49) -4.2 (-27.74 to 19.37) 70mg BID (N=51) +1.3 (-22.09 to 24.60) The Company has also reviewed data from several additional secondary endpoints of the Phase 2b portion of IMPAHCT, which also failed to show meaningful improvements. Based upon these results, Aerovate, in agreement with the independent study advisory committee, is halting enrollment and shutting down the Phase 3 portion of IMPAHCT as well as the long-term extension study. Aerovate plans to release full data from the Phase 2b portion of IMPAHCT at a later date, the timing of which is to be determined. As of June 15, 2024, Aerovate has approximately $100 million of cash, cash equivalents and short-term investments.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 99.1 Press release issued by Aerovate Therapeutics, Inc. on June 17, 2024, furnished herewith. 104 Cover Page Interactive Data File SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aerovate Therapeutics, Inc. Date: June 17, 2024 By: /s/ George A. Eldridge George A. Eldridge Chief Financial Officer